The AEMPS detects more supply alerts, but with less care impact

The AEMPS detects more medicine supply problems, but reduces to a minimum in five years the cases with the greatest impact on care.

Add DEMÓCRATA to Google

Ask FREN

Published

3 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 16 institutos

  • PP31,4 %
  • PSOE27,1 %
  • Vox18,9 %
  • Frente Amplio6,4 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

ELECCIONES 29N

¿Cuál es tu pronóstico? 29N

Reparte los 350 escaños del Congreso como creas que quedarán el 29 de noviembre. Puedes cambiar tu pronóstico hasta que cierren los colegios.

0 de 350 escaños

PP
PSOE
Vox
Frente Amplio
ERC
Junts
EH Bildu
PNV
Más partidos
Podemos
BNG
SALF
CC
UPN
Adelante
Aliança
Otros

Protegido por reCAPTCHA de Google: privacidad y condiciones

Pronóstico de DemócrataParticipación abierta, no es una encuesta

The Spanish Agency of Medicines and Health Products (AEMPS) identified supply incidents in 4.28% of the 33,308 marketing presentations in Spain during the first half of 2026. However, problems with the greatest impact on care were reduced to 0.17%, the lowest percentage recorded in the last five years.

In total, supply difficulties were reported in 1,426 medication presentations in the first six months of the year, according to the AEMPS half-yearly report on supply problems. The document highlights that 95.72% of the presentations maintained normal supply and points out that the increase in notifications could be linked to earlier communication by the marketing authorization holders, driven by the Agency’s awareness-raising and follow-up actions.

During the period analyzed, 58 new presentations affected by supply problems with a major impact were recorded, that is, those in which the availability of therapeutic alternatives and the possible clinical consequences for patients confer greater criticality. The proportion of these cases rose from 0.24% in the second half of 2025 to 0.17% in the first half of 2026.

Of those 58 presentations with problems of major impact, 32 were already resolved at the time the report was prepared. Ten incidents were closed in less than a month, 16 were prolonged between one and three months, and six extended beyond three months.

Manufacturing capacity, the main source of the problems

Among the reasons communicated by the laboratories, capacity limits at production plants accounted for 39.55% of the cases, followed by the increase in demand (22.79%) and manufacturing incidents not linked to quality defects (16.97%). The AEMPS clarifies that the same supply problem may be due to several simultaneous causes.

Medicines dispensed in pharmacy offices with a medical prescription accounted for 69.57% of the incidents recorded, while those for exclusive hospital use accounted for 18.44%. By therapeutic areas, the nervous system group was the most affected, with 386 presentations, followed by the cardiovascular system, with 265; antineoplastic and immunomodulating agents, with 169, and systemic anti-infectives, with 110.

394 exceptional marketing authorizations to ensure supply

To address supply problems, AEMPS authorized 394 exceptional marketing authorizations during the semester and ordered 353 export stops to other Member States of the European Union and 63 to third countries, in order to protect the available stock in the Spanish market. In addition, it resorted 25 times to the import of foreign medicines.

Compared with the second half of 2025, exceptional marketing authorizations increased from 243 to 394, which, according to the Agency, reflects the importance of this instrument for reducing the impact of the supply problems detected during the period.

Among the most relevant incidents is that of Tronoxal, which contains ifosfamide and whose production was conditioned by problems at a German plant. The company resumed supply on April 16, although AEMPS continues to monitor inventories. Difficulties were also reported with injectable cyclophosphamide, whose supply was ensured through controlled distribution of alternatives, exceptional marketing of units, and importation of medicines.

The report also details the situation of Trigon Depot, whose supply was resumed on July 9, although it continues to be subject to controlled distribution and support through imports; and of Celestone, whose units are being released on a continuous basis from July 11, with total normalization expected by the end of November.

In the case of Lenzetto, used as a hormone replacement therapy and also off-label as a feminizing hormone treatment, the supply problem was caused by the lack of availability of the applicator device. The laboratory communicated at the beginning of November the restart of supply, which is being recovered gradually through a controlled distribution that covers 75% of the demand prior to the start of the incident.